JL
John Lambert
Chief Executive Officer at Amplia Therapeutics
View John's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Chief Executive Officer
Present
Company Details
2-10 Employees
Despite the recent success of immuno-oncology drugs, their use in fibrotic cancers (pancreatic, ovarian cancer) has been met with limited success. Recent research shows that Focal Adhesion Kinase (FAK) is significantly upregulated in these highly fibrotic tumours and therefore drugs targeting FAK have the potential to sensitize the tumour micro-environment to both I-O and chemotherapies. Inhibiting FAK can also directly boost the number of immune cells responsible for attacking tumours, further “amplifying” the effect of immuno-oncology treatment. Amplia Therapeutics Limited is a pharmaceutical company advancing a pipeline of FAK inhibitors for cancer and fibrosis. The lead molecule, AMP945, is a “pure play” inhibitor with superior specificity. The second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways – VEGFR3 and FLT3.
Year Founded
2016
Social Media
Linkedin
Industry
Pharmaceutical Manufacturing, Scientific Research and Development Services, Services
HQ Location
Level 17, 350 Queen Street Melbourne, Victoria 3000, AU
Keywords
drug designationssupports cellpipeline drugspipeline cancer programdisease drug targetsaccent pancreaticpotent inhibitorkey disease drugtissue shieldfocal adhesion
Discover More About Cleveland Clinic

Find verified contacts of John Lambert in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.